Baonuo Pharmaceutical

Baonuo Pharmaceutical is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule drugs for oncology and other life-threatening diseases. The company leverages a proprietary structure-based drug design (SBDD) platform to target challenging oncogenic drivers, with a particular emphasis on the RAS/MAPK signaling pathway. Its lead programs include highly selective inhibitors targeting various KRAS mutations, such as G12D and G12C, as well as upstream regulators like SOS1 and SHP2. Headquartered in China, Baonuo aims to provide next-generation precision medicines for patients with difficult-to-treat solid tumors, including lung, colorectal, and pancreatic cancers.